NeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell
April 20 2017 - 11:02AM
What:NeuroDerm Ltd. (Nasdaq:NDRM), a clinical
stage pharmaceutical company developing drug-device combinations
for central nervous system (CNS) disorders, will visit the Nasdaq
MarketSite in Times Square.
In honor of the occasion, Oded Lieberman, Chief
Executive Officer, will ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Friday, April 21, 2017 – 9:15 a.m. to 9:30
a.m. ET
NeuroDerm Media Contact:Erich SandovalLazar
Partners Ltd.esandoval@lazarpartners.com+917-497-2867
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical
company developing drug-device combinations for central nervous
system (CNS) disorders that are designed to overcome major
deficiencies of current treatments and achieve enhanced clinical
efficacy through continuous, controlled
administration. NeuroDerm has three product candidates in
different stages of development which offer a solution for almost
every Parkinson’s disease patient from the moderate to the very
severe stage of the disease. NeuroDerm has developed a
line of levodopa and carbidopa (LD/CD) product candidates
administered through small belt pumps that deliver a continuous,
controlled dose of LD/CD. The LD/CD product candidates are ND0612L
and ND0612H, which are used for treatment of moderate and advanced
Parkinson’s disease patients, respectively, and which are delivered
subcutaneously. In addition, NeuroDerm is developing
ND0701, a novel subcutaneously delivered apomorphine formulation
for patients who suffer from moderate to severe Parkinson’s disease
and who do not respond well to LD/CD. NeuroDerm is
headquartered in the Weizmann Science Park in
Rehovot, Israel.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables clients
to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 85 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
approximately 3,800 listed companies with a market value of $10.1
trillion and nearly 18,000 corporate clients. To learn more, visit:
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024